Medication info
Trulicity M 2.5/850 mg (linagliptin, metformin hydrochloride)

Trulicity M 2.5/850 mg (linagliptin, metformin hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›850mg / 1 tablet
Manufacturer / importer
Boryung Co., Ltd.
Appearance
Bright orange, double convex, oval shaped film-coated tablet
Packaging
30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle
Approval status
Active

MFDS item code 201902370 · Approved 2019.04.17 · Insurance code 641906960

Summary

Main use
Improvement of glycemic control in type 2 diabetes
Who takes it
Adults
Adult dose
The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Ingredients

Manufacturer
Boryung Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes

View approved original text

This medication assists in the blood sugar control of patients with type 2 diabetes by using linagliptin and metformin together. When administered alongside dietary and exercise therapy, it helps to effectively improve blood sugar levels. Through this, it can make blood sugar management smoother for the patient. When used safely, a positive effect on diabetes treatment can be expected.

How to take

Adult dose

The dose of this medicine should be determined according to each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of each component: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medicine is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently treated with metformin: For patients who have not previously received pharmacological treatment for diabetes and whose blood glucose is inadequately controlled with monotherapy, the initial dose is 1 tablet of this medicine 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 2.5/1000 mg twice daily. 2. Patients whose blood glucose is inadequately controlled with metformin monotherapy: The initial dose of this medicine should provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and the patient's current dose of metformin (e.g., a patient taking metformin 1000 mg twice daily should take linagliptin 2.5 mg/metformin 1000 mg twice daily with meals). 3. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medicine should start at their current doses of linagliptin and metformin. 4. Patients whose blood glucose is inadequately controlled with combination therapy of metformin and a sulfonylurea: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with a sulfonylurea, a reduction in the sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). 5. Patients whose blood glucose is inadequately controlled with combination therapy of insulin and metformin: The initial dose of this medicine should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medicine is administered in combination with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 3. Patients Requiring Caution). No studies have been conducted to evaluate the safety and efficacy of switching to this medicine in patients previously treated with another oral antihyperglycemic agent. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who have no other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medicine. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine must be discontinued immediately. Patients with hepatic impairment This medicine should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients in Whom This Medicine Must Not Be Used).

Precautions

This medication is primarily used for blood sugar control. It contains two main ingredients, one of which is predominantly excreted by the kidneys, so patients with decreased kidney function should not take this medication. Lactic acidosis, a serious side effect, may occur rarely, as it can accumulate excessively in the body and become severe, so caution is needed. This medication should not be administered to individuals with allergic reactions to it or with certain heart, liver, or kidney diseases. Women who are pregnant or breastfeeding are recommended not to use this medication, and it is not recommended for children and adolescents. During the use of this medication, symptoms of hypoglycemia may appear, so blood sugar levels should be closely monitored, especially when used in conjunction with other hypoglycemic agents. In certain situations such as surgeries or radiological tests, it may be necessary to temporarily discontinue this medication, and safety should be confirmed through kidney function tests before resuming use. This medication may cause some gastrointestinal disturbances, headaches, fatigue, rashes, and in rare cases, acute pancreatitis or skin conditions; therefore, any abnormal symptoms should be discussed with a physician immediately. Additionally, this medication may interact with other medications, so if you are taking other drugs, be sure to inform your healthcare provider.

Side effects

Lactic acidosis, hypoglycemia, dysgeusia, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcer formation, abnormal liver function tests, hepatitis, pruritus, erythema, rash, vesicular pemphigoid, severe arthritis with disabilities, rhabdomyolysis, increased lipase, increased amylase, nasopharyngitis, hypersensitivity, angioedema, urticaria, decreased and deficiency of vitamin B12, oral ulcers, abnormal liver function, constipation, upper abdominal pain, small intestinal and colonic inflammation, intestinal obstruction, gastritis, shingles, cystitis, acute pyelonephritis, bronchitis, vestibular neuritis, sepsis, pneumonia, loss of appetite, dehydration, hyperglycemia, cerebral infarction, speech disorders, Alzheimer's dementia, chest pain, fever, facial edema, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage kidney disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, mood disorders, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, itching, hypertension, erectile dysfunction, goiter, confusion, nocturia, dermatitis, hypertension, angina, acute myocardial infarction, unstable angina, stomatitis, mediastinitis, vitreous hemorrhage, fever, ligament sprain, flank pain, myelodysplastic syndrome, vocal cord polyp, dyspepsia, upper abdominal pain, rectal bleeding, cheilitis, cavities, enteritis, gastritis, stomatitis, dizziness, sensory loss, chest pain, discomfort in the chest, weakness, pain, nosebleed, oropharyngeal pain, voice disorders, shortness of breath, epistaxis, hearing loss, benign prostatic hyperplasia, male-pattern hair loss, hyperhidrosis, hair loss, skin lesions, dermatitis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a tightly sealed container. It is advisable to maintain storage temperatures between 1 to 30 degrees Celsius to effectively preserve the medication's efficacy.

Appearance and packaging

Appearance

Bright orange, double convex, oval shaped film-coated tablet

Package unit

30 tablets/bottle, 60 tablets/bottle, 100 tablets/bottle, 200 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.